search
Back to results

EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT

Primary Purpose

Knee Osteoarthritis

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Arteriography knee arteriography
Sponsored by
Centre Hospitalier Universitaire de Nice
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Knee Osteoarthritis

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Man or woman aged 40 to 80.
  • Total knee joint or bilateral Pain with EVA ≥ 50 mm evolving for at least 3 months despite the initiation of a well conducted medical treatment according to current recommendations including analgesics, NSAIDs, rehabilitation and weight loss

Exclusion Criteria:

  • Minor person.
  • Protected adults under the law. Patients deprived of their liberties. Subject not cooperative or unable to meet the requirements of the protocol.
  • Subject participating in another clinical trial or in period of exclusion from a previous clinical trial. Severe visceral failure.
  • Local infection. Algoneurodystrophy.
  • Prosthesis loosening.
  • Pregnant or breastfeeding woman.
  • Allergy to contrast media.
  • Chronic or acute renal failure (clearance <30 ml / min).
  • Hemostasis disorders (blood platelet count <50,000 / mm3 or patient TCA / control TCA> 1.2 or TP <50%).
  • Operative indication for removal of the retained prosthesis.
  • Patient with obliterating arterial disease of the lower limbs.
  • Contraindication to lidocaine: Known hypersensitivity to lidocaine hydrochloride, to local amide anesthetics or to any of the excipients.
  • Patients with recurrent porphyria

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Other

    Arm Label

    ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS

    Arm Description

    SYMPTOMATIC EFFECTIVENESS OF MICROPARTICLE ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT

    Outcomes

    Primary Outcome Measures

    Knee injury self-questionnaire
    modification of the pain item in the Knee injury self-questionnaire collected
    Knee injury self-questionnaire
    modification of the pain item in the Knee injury self-questionnaire collected
    Osteoarthritis Outcome Score (KOOS) self-questionnaire
    and Osteoarthritis Outcome Score (KOOS) self-questionnaire collected
    Osteoarthritis Outcome Score (KOOS) self-questionnaire
    and Osteoarthritis Outcome Score (KOOS) self-questionnaire collected

    Secondary Outcome Measures

    EVA (Analog Visual Scale)
    EVA (Analog Visual Scale) score from 0 to 10
    EVA (Analog Visual Scale)
    EVA (Analog Visual Scale) score from 0 to 10
    EVA (Analog Visual Scale)
    EVA (Analog Visual Scale) score from 0 to 10
    Osteoarthritis Outcome Score (KOOS) self-questionnaire
    KOOS
    Osteoarthritis Outcome Score (KOOS) self-questionnaire
    KOOS
    Osteoarthritis Outcome Score (KOOS) self-questionnaire
    KOOS
    EQ-5D (quality of life scale)
    EQ-5D (quality of life scale)
    EQ-5D (quality of life scale)
    EQ-5D (quality of life scale)

    Full Information

    First Posted
    July 24, 2020
    Last Updated
    September 22, 2020
    Sponsor
    Centre Hospitalier Universitaire de Nice
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04566315
    Brief Title
    EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT
    Official Title
    SYMPTOMATIC EFFECTIVENESS OF MICROPARTICLE ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 1, 2020 (Anticipated)
    Primary Completion Date
    October 1, 2021 (Anticipated)
    Study Completion Date
    April 1, 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Centre Hospitalier Universitaire de Nice

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The objective of this study is to evaluate at 3 months in a prospective study, the effectiveness of arterial embolization of neo-vessels in patients with a painful total knee prosthesis despite a well-conducted medical treatment
    Detailed Description
    To date, no study has attempted to measure the effects of arterial embolization on pain in patients with total knee prosthesis. It would be interesting to evaluate, in a therapeutic trial with a good level of evidence, this alternative to drug treatments that are often poorly tolerated, contraindicated or failing in this population of elderly subjects often presenting co-morbidities. This pilot study will be used to calculate the number of patients to be included in a comparative, placebo-controlled, double-blind study. In addition to the evaluation of the undesirable effects of arterial embolization, the objective of this study is to evaluate the effectiveness at 3 and 6 months of embolization of the neovessels on pain, stiffness, physical activity, quality of life and consumption of analgesics and anti-inflammatories. Evaluation criteria: modification of the pain item in the EVA (Analog Visual Scale), EQ-5D (quality of life scale), and Knee injury and Osteoarthritis Outcome Score (KOOS) self-questionnaire collected in the 15 days preceding the procedure and then at 3 and 6 months ; the use of analgesics and anti-inflammatories; adverse events. Study population: Patients aged 40 to 80 years with a painful total knee joint. The visual analogue scale (VAS) score must be greater than or equal to 50 mm for at least 3 months optimal medical treatment, and for whom, no surgical retreatment is indicated. The expected benefits are the improvement of the treatment of patients in therapeutic impasse, wearing a total knee prosthesis whose pain is rebellious and disabling. More generally, the investigators expect an improvement in the quality of life of these patients currently without satisfactory alternative care.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Knee Osteoarthritis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    10 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS
    Arm Type
    Other
    Arm Description
    SYMPTOMATIC EFFECTIVENESS OF MICROPARTICLE ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT
    Intervention Type
    Procedure
    Intervention Name(s)
    Arteriography knee arteriography
    Intervention Description
    arteriography and an injection of inert microparticles of 75 μm in neovessels
    Primary Outcome Measure Information:
    Title
    Knee injury self-questionnaire
    Description
    modification of the pain item in the Knee injury self-questionnaire collected
    Time Frame
    in the 15 days preceding the procedure
    Title
    Knee injury self-questionnaire
    Description
    modification of the pain item in the Knee injury self-questionnaire collected
    Time Frame
    at 3 months
    Title
    Osteoarthritis Outcome Score (KOOS) self-questionnaire
    Description
    and Osteoarthritis Outcome Score (KOOS) self-questionnaire collected
    Time Frame
    in the 15 days preceding the procedure
    Title
    Osteoarthritis Outcome Score (KOOS) self-questionnaire
    Description
    and Osteoarthritis Outcome Score (KOOS) self-questionnaire collected
    Time Frame
    at 3 months
    Secondary Outcome Measure Information:
    Title
    EVA (Analog Visual Scale)
    Description
    EVA (Analog Visual Scale) score from 0 to 10
    Time Frame
    in the 15 days preceding the procedure ,
    Title
    EVA (Analog Visual Scale)
    Description
    EVA (Analog Visual Scale) score from 0 to 10
    Time Frame
    at 3 months
    Title
    EVA (Analog Visual Scale)
    Description
    EVA (Analog Visual Scale) score from 0 to 10
    Time Frame
    at 6 months
    Title
    Osteoarthritis Outcome Score (KOOS) self-questionnaire
    Description
    KOOS
    Time Frame
    in the 15 days preceding the procedure,
    Title
    Osteoarthritis Outcome Score (KOOS) self-questionnaire
    Description
    KOOS
    Time Frame
    at 3 months,
    Title
    Osteoarthritis Outcome Score (KOOS) self-questionnaire
    Description
    KOOS
    Time Frame
    at 6 months,
    Title
    EQ-5D (quality of life scale)
    Description
    EQ-5D (quality of life scale)
    Time Frame
    in the 15 days preceding the procedure
    Title
    EQ-5D (quality of life scale)
    Description
    EQ-5D (quality of life scale)
    Time Frame
    at 3 months,

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    40 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Man or woman aged 40 to 80. Total knee joint or bilateral Pain with EVA ≥ 50 mm evolving for at least 3 months despite the initiation of a well conducted medical treatment according to current recommendations including analgesics, NSAIDs, rehabilitation and weight loss Exclusion Criteria: Minor person. Protected adults under the law. Patients deprived of their liberties. Subject not cooperative or unable to meet the requirements of the protocol. Subject participating in another clinical trial or in period of exclusion from a previous clinical trial. Severe visceral failure. Local infection. Algoneurodystrophy. Prosthesis loosening. Pregnant or breastfeeding woman. Allergy to contrast media. Chronic or acute renal failure (clearance <30 ml / min). Hemostasis disorders (blood platelet count <50,000 / mm3 or patient TCA / control TCA> 1.2 or TP <50%). Operative indication for removal of the retained prosthesis. Patient with obliterating arterial disease of the lower limbs. Contraindication to lidocaine: Known hypersensitivity to lidocaine hydrochloride, to local amide anesthetics or to any of the excipients. Patients with recurrent porphyria
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jacques Sedat, MD
    Phone
    0492033807
    Email
    sedat.j@chu-nice.fr
    First Name & Middle Initial & Last Name or Official Title & Degree
    Marion Causeret
    Phone
    00033492034702
    Email
    causeret.m@chu-nice.fr
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jacques Sedat, MD
    Organizational Affiliation
    Centre Hospitalier Universitaire de Nice
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT

    We'll reach out to this number within 24 hrs